Document is current
Any future updates will be listed below
-
Authors
Xu, Shi
Lam, Sze-Kwan
Cheng, Paul Ning-Man
Ho, James Chung-Man https://orcid.org/0000-0003-4499-5284
- License Information
-
More Information
Article History
Received: 30 January 2019
Accepted: 6 August 2019
First Online: 19 August 2019
Competing Interests
: Paul Ning-Man Cheng is the chief executive officer of Bio-Cancer Treatment International Limited and holds stocks or shares in Bio-Cancer Treatment International Limited. The other authors have no conflict of interest.
